Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784387 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07784387 · ClinicalTrials.gov record · last posted 2026-08-25

A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

Name: A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal — clinical trial record (NCT07784387)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BRITE

StatusRecruiting

PhaseNot specified

SponsorJanssen-Cilag Farmaceutica Ltda.

Started2026-08-31

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.

Trial Details

NCT Number	NCT07784387
Lead Sponsor	Janssen-Cilag Farmaceutica Ltda.
Conditions	Urinary Bladder Neoplasms
Enrollment	250 participants
Start Date	2026-08-31
Primary Completion	2028-02-15 (estimated)
Study Completion	2028-02-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-25